Prenyl transferase (farnesyl pyrophosphate synthase) and/or isopentenyl pyrophosphate isomerase inhibitors find application in various forms of the therapy and prophylaxis.

Iron is present in the form of soluble ferric pyrophosphate.

Fibrous calcium pyrophosphate particles with a unique fibrous nanostructure are disclosed.

Other crystallisation inhibitors such as pyrophosphate may be present.

The light-transmitting binder comprises light-reflecting particles.

Described herein are therapeutic compositions comprising a therapeutic agent and pyrophosphate.

Synthesis of all higher terpenoids proceeds via formation of geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP).

A method for producing such a piperazine pyrophosphate at low cost is also disclosed wherein the piperazine pyrophosphate is produced through dehydration condensation of a piperazine diphosphate.

Synthesis of all higher terpenoids proceeds via formation of geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP).

The present invention provides a method for efficiently producing, at high yields, pyrophosphate, particularly melamine pyrophosphate, which is useful as a flame retardant.

Synthesis of all higher terpenoids proceeds via formation of geranyl pyrophosphate (GPP), farnesyl pyrophosphate (FPP), and geranylgeranyl pyrophosphate (GGPP).

The light-reflecting particles are chosen from a group formed by titanium oxide, aluminum oxide, halophosphates, calcium pyrophosphate, and strontium pyrophosphate.

Three molecules of isopentenyl pyrophosphate condense to form farnesyl pyrophosphate through the action of geranyl transferase.

The present invention provides methods for enhancing and reducing the levels of IPP, DMAPP and/or isoprenoids in a host cell.

Three molecules of isopentenyl pyrophosphate condense to form farnesyl pyrophosphate through the action of geranyl transferase.